DEA Revokes De Novo Services' Drug Handling License Over Decade of Sloppiness
Published Date: 4/23/2025
Notice
Summary
De Novo Services, LLC lost its DEA registration because it didn’t keep good control over controlled substances and broke recordkeeping rules from 2013 to 2023. Since they didn’t ask for a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle these drugs anymore. This affects De Novo directly and signals a strict stance on drug safety and record rules.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for De Novo
De Novo Services, LLC (DEA Certificate No. RD0424515) had its DEA registration revoked for failures to control and account for controlled substances between 2013 and 2023. Because De Novo did not request a hearing, the DEA entered a final order revoking the registration effective May 23, 2025.
Pending Renewal and New Applications Denied
The DEA denied any pending applications by De Novo Services, LLC to renew or modify its registration and denied any other pending application by De Novo for additional registration in Utah. Those denials accompany the revocation order and are part of the final agency action.
Final Adjudication Creates Public Record and Deterrence
The DEA adjudicated this matter to finality to create an official public record to educate current and prospective registrants about their responsibilities and to inform stakeholders of the Agency's enforcement priorities. The decision states that specific and general deterrence weighed in favor of revocation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
2026-17385, Importer of Controlled Substances Application: Experic LLC
Experic LLC wants to become an official importer of some controlled substances, including certain drugs like tetrahydrocannabinols and nabilone. People and companies already registered can share their thoughts or ask for a hearing by September 25, 2026. This move could impact businesses dealing with these substances, so keep an eye on the deadline to have your say!
2026-17275, Catina Allen, N.P.; Decision and Order
Catina Allen, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
2026-17285, Importer of Controlled Substances Application: Prof Compounding CTS of Ameri
Prof Compounding CTS of Ameri has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Previous / Next Documents
Previous: 2025-07025, Extension of Agency Information Collection Activity Under OMB Review: Enhanced Security Procedures at Ronald Reagan Washington National Airport
The TSA is asking to keep collecting info from small plane pilots and armed security officers at Ronald Reagan Washington National Airport. Pilots need to pick a security coordinator and follow special safety rules. This helps keep everyone safe without adding extra costs or delays.
Next: 2025-07029, Draft Aquaculture Opportunity Area Options-Alaska State Waters
NOAA is exploring spots in Alaska’s state waters where fish farms could grow and thrive, aiming to boost local seafood business and jobs. They’ve picked some draft areas and want your thoughts before making final decisions. This is a big step toward smarter, eco-friendly aquaculture, with public input shaping the future and no money changes yet.